Markets & Investing
Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction
Vancouver, British Columbia–(Newsfile Corp. – January 29, 2024) – Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a western…
Vancouver, British Columbia–(Newsfile Corp. – January 29, 2024) – Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a western Canadian-based life sciences company, is pleased to report that it has received its first shipment of “SOSA”, a leading addictions focused herbal treatment.
SOSA is a patented, WHO-approved, herbal treatment for opiate addiction that has been administered to more than 30 million patients in Asia. SOSA is registered with the health authorities in China, Indonesia, Thailand, Vietnam, and Cambodia and has been used to safely and effectively treat opiate addictions in these countries for over twenty years. A report from the WHO concluded that SOSA can be used “safely and effectively for heroin and other opiates addiction treatment, detoxification and acute heroin withdrawal symptoms. In addition, the side effects are minimal and tolerable.”
SOSA has been proven to be effective at breaking the cycle of addiction to opioids and other opiate-based addictive drugs.
The US Council of Economic Advisors estimates the cost of the Opioids Crisis to the US economy at more than $500 billion annually, this equates to almost 4% of GDP. In 2021, more than 75,000 Americans died of drug overdose, with around two-thirds of those deaths linked to opioids. The impact can be measured financially, with massive health care and insurance costs as well as the significant costs of law enforcement. It has been estimated that it will require a large investment, as much as $100 billion, to fully address the crisis.
This first shipment will be used for analysis and pre-clinical trials. The Company expects to commence selected trials and finalize distribution contracts in the coming weeks.
“We believe that the SOSA product can be a game changer in the effort to help those afflicted with opiates addiction-related disorders. The Nirvana project was formed with the belief that innovation can make a difference to people affected by this crisis.”
– Bruce Clark, CEO of Nirvana Life Sciences
About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that mitigate the symptoms of chronic pain and support patients who battle with addiction. Nirvana believes that pairing naturally sourced psychedelics with modern medicine holds the promise of delivering non-addictive therapeutic solutions. Backed by a team of global leading researchers, Nirvana will develop life changing therapies for those suffering from pain and addiction and consequently alleviate the fiscally strained medical system.
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment